Skip to content
Screener

Cytokinetics CYTK Other Non-Current Assets

Other Non-Current Assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$6.38B+7.4%
Eli Lilly logo
Eli LillyLLY
$7.48B+20.2%
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$368K0.0%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$1.53M+505%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$10.83M+32.2%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$138K-50.4%

Other financials

Income statement

See full
Revenue$28.6M-57.1%
Operating income-$179.2M-60.7%
Net income-$198.8M-47.9%
EPS (diluted)-$1.50-33.9%

Balance sheet

See full
Cash & equivalents$255.3M+241%
Total debt$399.0M+31.2%
Total equity-$173.5M+52.9%
Total assets$1.9B+57.0%

Cash flow

See full
Operating cash flow-$159.8M-24.6%
CapEx$4.3M+4.6%
Free cash flow-$164.2M-24.0%

Valuation

See full
Market cap$10.71B+155%
Enterprise value$10.85B+145%
P/S158.2×+109×

Profitability

See full
Operating margin-1,046.1%+1,858pp
Net margin-1,321.1%+8,702pp
FCF margin-858.2%+1,799pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio6.7×-0.1×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338217
Line itemJune 30, 2026December 31, 2025
Property and equipment, net78,91679,194
Operating lease right-of-use assets72,89675,979
Inventories, long-term6,529
Other assets19,40617,341
Total assets$1,924,551$1,424,537
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable$20,510$22,337

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Cytokinetics's other non-current assets?
Cytokinetics (CYTK) reported other non-current assets of $19.41M in Q2 2026.
How has Cytokinetics's other non-current assets changed year-over-year?
Cytokinetics's other non-current assets increased by 33.3% year-over-year, from $14.55M to $19.41M.
What is the long-term trend for Cytokinetics's other non-current assets?
Over 5 years (2020 to 2025), Cytokinetics's other non-current assets has grown at a 22.2% compound annual growth rate (CAGR), from $6.36M to $17.34M.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.

Ask your AI about Cytokinetics's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude